We believe that DexCom, best known for its continuous glucose monitoring systems, currently is an attractive pick over Amedisys stock (NASDAQ: AMED), a home health and hospice company with a similar revenue base, despite Dexcom's comparatively higher valuation. DXCM stock trades at 16.3x trailing...
We believe that DexCom, best known for its continuous glucose monitoring systems, currently is an attractive pick over Amedisys stock (NASDAQ: AMED), a home health and hospice company with a similar revenue base, despite Dexcom's comparatively higher valuation. DXCM stock trades at 16.3x trailing...
Share this Article
Recommended